Brendan O'Leary

Mr Brendan O'Leary, PhD


As a member of the life science team, Brendan focuses on companies in the pharmaeutical, medical device, and diagnostic sectors. His current investments include Proteon Therapeutics, ROX Medical, and Trius Therapeutics (NASDAQ: TSRX). He was formerly on the board of BioRexis Pharmaceutical Corporation, which was acquired by Pfizer (NYSE: PFE), Serica Technologies acquired by Allergan (NYSE: AGN), Atritech acquired by Boston Scientific (NYSE: BSX), and Alacer Biomedical also acquired by Allergan. Prism's current and prospective portfolio companies benefit from Brendan's diverse technical background, deep operating experience and extensive industry contacts. He has over a dozen years of experience in the biotechnology and medical technology arenas and has held numerous senior operating positions at companies such as Meso Scale Discovery, a high throughput drug discovery start-up, and IGEN International, a leading medical diagnostics company (acquired by Roche). He is also an accomplished scientist with numerous publications, inventions and commercialized products to his credit. Brendan's combined experiences have added significant value to Prism's portfolio, particularly in moving exciting technologies from bench to bedside.
Brendan received his Ph.D. in Organic Chemistry from the Massachusetts Institute of Technology. He holds a B.A. in Chemistry and Economics from Middlebury College. Brendan was also a Kauffman Fellow.


Associate (Needham) (current)

Prism VentureWorks

(Prism Venture Partners)

Principal (Needham) (current)

Add education